VEGFR2/CD309 anticorps (AA 101-200)

N° du produit ABIN2180045

Détail du produit anti-VEGFR2/CD309 anticorps

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Épitope: AA 101-200

Reactivité: Humain, Souris, Rat, Lapin

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGFR2/CD309 est non-conjugé

Application: ELISA, Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Réactivité croisée: Humain, Souris, Lapin, Rat

Homologie: Dog,Cow,Sheep,Pig,Horse

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human VEGFR2

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Références pour anticorps anti-VEGFR2/CD309 (ABIN2180045)

Wang, Chen, Ke, Li: "Ghrelin inhibits atherosclerotic plaque angiogenesis and promotes plaque stability in a rabbit atherosclerotic model." dans: Peptides, Vol. 90, pp. 17-26, (2017) (PubMed).

Xiao, Wang, Yan, Lv, Zhao, Zhou, Zhang, Sun, Sun, Li, Lu: "Adipose-derived stem cells-seeded bladder acellular matrix graft-silk fibroin enhances bladder reconstruction in a rat model." dans: Oncotarget, Vol. 8, Issue 49, pp. 86471-86487, (2017) (PubMed).

Tan, Yang, Fu, Cui, Guo, Ma, Yin, Leng, Song: "Single-dose local simvastatin injection improves implant fixation via increased angiogenesis and bone formation in an ovariectomized rat model." dans: Medical science monitor : international medical journal of experimental and clinical research, Vol. 21, pp. 1428-39, (2015) (PubMed).

García Fernández, Sánchez Pérez, Sánchez Maldonado, García-Palencia, Naranjo Freixa, Palomo Yagüe, Flores: "Iberian pig early pregnancy: vascular endothelial growth factor receptor system expression in the maternofetal interface in healthy and arresting conceptuses." dans: Theriogenology, Vol. 83, Issue 3, pp. 334-43, (2014) (PubMed).

Kuang, Yang, Zhang, Zhang, Wu: "Schlafen 1 inhibits the proliferation and tube formation of endothelial progenitor cells." dans: PLoS ONE, Vol. 9, Issue 10, pp. e109711, (2014) (PubMed).

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: VEGFR2 (VEGFR2 Produits)

Synonymes: anticorps CD309, anticorps FLK1, anticorps VEGFR, anticorps VEGFR2, anticorps 6130401C07, anticorps Flk-1, anticorps Flk1, anticorps Krd-1, anticorps Ly73, anticorps VEGFR-2, anticorps sVEGFR-2, anticorps Vegfr-2, anticorps FLK-1, anticorps flk-1, anticorps vegfr-2, anticorps KDR, anticorps FLK/KDR, anticorps flk1, anticorps flk1b, anticorps kdrb, anticorps si:busm1-205d10.1, anticorps si:ch211-254j6.1, anticorps si:ch211-278f21.4, anticorps wu:fc31a09, anticorps fk52c05, anticorps flk, anticorps kdr, anticorps kdra, anticorps vegfr2, anticorps vegfr4, anticorps vegr2, anticorps wu:fk52c05, anticorps kinase insert domain receptor, anticorps kinase insert domain protein receptor, anticorps vascular endothelial growth factor receptor kdr-like, anticorps kinase insert domain receptor (a type III receptor tyrosine kinase), anticorps kinase insert domain receptor like, anticorps KDR, anticorps Kdr, anticorps LOC100136647, anticorps kdr, anticorps kdrl

Sujet:

Synonyms: FLK1, CD309, VEGFR, VEGFR2, Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, FLK-1, Kinase insert domain receptor, KDR, Protein-tyrosine kinase receptor flk-1

Background: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

ID gène: 3791

UniProt: P35968

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling